Exact Sciences Corp (EXAS) 22.57 $EXAS
SmarTrend Watching for Potential Pullback in Shares of Exact Sciences After 6.31% Gain
Comtex SmarTrend(R) - 2 hrs 38 mins ago
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $21.59 to a high of $23.20. Yesterday, the shares gained 6.3%, which took the trading range above the 3-day high of $22.00 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Exact Sciences Has Returned 21.3% Since SmarTrend Recommendation (EXAS)
Comtex SmarTrend(R) - Wed Sep 03, 9:50AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on August 12th, 2014 at $18.18. In approximately 3 weeks, Exact Sciences has returned 21.27% as of today's recent price of $22.04.
Exact Sciences to participate in Baird's 2014 Health Care Conference
Business Wire - Thu Aug 28, 3:30PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in Baird's 2014 Health Care Conference in New York.
Shares of EXAS Up 18.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 27, 9:21AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on August 12th, 2014 at $18.18. In approximately 2 weeks, Exact Sciences has returned 18.24% as of today's recent price of $21.49.
SmarTrend Watching for Potential Pullback in Shares of Exact Sciences After 1.85% Gain
Comtex SmarTrend(R) - Tue Aug 26, 4:29PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $21.04 to a high of $22.01. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $21.45 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America
at The Street - Mon Aug 25, 7:00PM CDT
Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.
'Mad Money' Lightning Round: I Like Blackstone Group
at The Street - Tue Aug 26, 5:00AM CDT
Cramer's being careful with Barracuda Networks but he likes NuStar Energy, Exact Sciences and Amkor Technology.
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma
PR Newswire - Mon Aug 25, 7:50AM CDT
On Friday, August 22, 2014, the NASDAQ Composite ended at 4,538.55, up 0.14%, the Dow Jones Industrial Average declined 0.22%, to finish the day at 17,001.22, and the S&P 500 closed at 1,988.40, down 0.20%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day flat at 727.35, and the index has advanced 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Aeterna Zentaris Inc. (NASDAQ: AEZS), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at:
Exact Sciences Announces Mayo Clinic as First Healthcare System to Offer Cologuard(R)
Business Wire - Mon Aug 25, 7:00AM CDT
Exact Sciences Corp. (NASDAQ:EXAS) today announced that Mayo Clinic will be the first health system to offer Cologuard(R), the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer. Cologuard will be available to patients through their primary care physicians at Mayo Clinic.
Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:32AM CDT
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
Exact Sciences Rises 6.43% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Aug 20, 4:29PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $18.21 to a high of $19.85. Yesterday, the shares gained 6.4%, which took the trading range above the 3-day high of $18.42 on volume of 5.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest percentage increases
AP - Wed Aug 20, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
'Fast Money' Recap: Building on a Housing Recovery
at The Street - Wed Aug 20, 4:00AM CDT
The trading panel looked at Home Depot, home builders and Apple.
Drug Approvals, Financial Results, Market Activity, New Mobile Applications, and Company Updates - Research Reports on Intercept, Exact Sciences, Thermo Fisher Scientific, Illumina and Agilent
PR Newswire - Fri Aug 15, 8:00AM CDT
Today, Analysts Review released its research reports regarding Intercept Pharmaceuticals, Inc. (NASDQ: ICPT), Exact Sciences Corporation (NASDAQ: EXAS), Thermo Fisher Scientific, Inc. (NYSE: TMO), Illumina Inc. (NASDAQ: ILMN) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5768-100free.
Biotech Stock Mailbag: Exact Sciences, Galena, Amgen
at The Street - Fri Aug 15, 6:22AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Kate Spade and Flowers Foods are big market movers
AP - Tue Aug 12, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Exact Sciences (EXAS) Stock Is Gaining Today
at The Street - Tue Aug 12, 10:33AM CDT
Exact Sciences (EXAS) shares are climbing after the company's non-invasive cancer detection test was approved by the FDA.
FDA Approves Exact Sciences' Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test
PR Newswire - Tue Aug 12, 6:00AM CDT
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company's noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home.
FDA approves first DNA-based test for colon cancer
By MATTHEW PERRONE - AP - Mon Aug 11, 5:43PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Monday approved the first screening test for colon cancer that uses patients' DNA to help spot potentially deadly tumors and growths.
Exact Sciences Earnings Hindsight: Up 1.1% in Last 20 Days (EXAS)
Comtex SmarTrend(R) - Mon Aug 11, 12:22PM CDT
20 days ago, on July 22nd, 2014, Exact Sciences (NASDAQ:EXAS) reported its earnings. Analysts, on average, expected a loss of $0.24 per share on sales of $123.0 thousand. The company actually reported a loss of $0.24 per share on sales of $0.0 thousand, beating EPS estimates by $0.00 and matching revenue estimates. Shares of Exact Sciences have climbed from $16.49 to $16.67, representing a gain of 1.1% since the company reported earnings 20 days ago.
SmarTrend Watching for Potential Pullback in Shares of Exact Sciences After 6.31% Gain
Comtex SmarTrend(R) - 2 hrs 38 mins ago
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $21.59 to a high of $23.20. Yesterday, the shares gained 6.3%, which took the trading range above the 3-day high of $22.00 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Exact Sciences Has Returned 21.3% Since SmarTrend Recommendation (EXAS)
Comtex SmarTrend(R) - Wed Sep 03, 9:50AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on August 12th, 2014 at $18.18. In approximately 3 weeks, Exact Sciences has returned 21.27% as of today's recent price of $22.04.
Exact Sciences to participate in Baird's 2014 Health Care Conference
Business Wire - Thu Aug 28, 3:30PM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in Baird's 2014 Health Care Conference in New York.
Shares of EXAS Up 18.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 27, 9:21AM CDT
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on August 12th, 2014 at $18.18. In approximately 2 weeks, Exact Sciences has returned 18.24% as of today's recent price of $21.49.
SmarTrend Watching for Potential Pullback in Shares of Exact Sciences After 1.85% Gain
Comtex SmarTrend(R) - Tue Aug 26, 4:29PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $21.04 to a high of $22.01. Yesterday, the shares gained 1.9%, which took the trading range above the 3-day high of $21.45 on volume of 3.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Jim Cramer's 'Mad Money' Recap: Thank You, Corporate America
at The Street - Mon Aug 25, 7:00PM CDT
Corporate profits, not the Fed, are fueling ever higher stock prices, and that growth is only accelerating, Cramer says.
'Mad Money' Lightning Round: I Like Blackstone Group
at The Street - Tue Aug 26, 5:00AM CDT
Cramer's being careful with Barracuda Networks but he likes NuStar Energy, Exact Sciences and Amkor Technology.
Momentum Indicators for Biotech Stocks -- Exact Sciences, BioCryst Pharma, Spectrum Pharma, Aeterna Zentaris, and CTI BioPharma
PR Newswire - Mon Aug 25, 7:50AM CDT
On Friday, August 22, 2014, the NASDAQ Composite ended at 4,538.55, up 0.14%, the Dow Jones Industrial Average declined 0.22%, to finish the day at 17,001.22, and the S&P 500 closed at 1,988.40, down 0.20%. The losses were broad based as seven out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day flat at 727.35, and the index has advanced 6.75% in the previous three months. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), Aeterna Zentaris Inc. (NASDAQ: AEZS), and CTI BioPharma Corporation (NASDAQ: CTIC). Free research on these five companies can be accessed at:
Exact Sciences Announces Mayo Clinic as First Healthcare System to Offer Cologuard(R)
Business Wire - Mon Aug 25, 7:00AM CDT
Exact Sciences Corp. (NASDAQ:EXAS) today announced that Mayo Clinic will be the first health system to offer Cologuard(R), the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer. Cologuard will be available to patients through their primary care physicians at Mayo Clinic.
Exact Sciences Corporation (EXAS) Jumps: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 8:32AM CDT
Exact Sciences Corporation (EXAS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
Exact Sciences Rises 6.43% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Aug 20, 4:29PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $18.21 to a high of $19.85. Yesterday, the shares gained 6.4%, which took the trading range above the 3-day high of $18.42 on volume of 5.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Nasdaq stocks posting largest percentage increases
AP - Wed Aug 20, 12:50PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
'Fast Money' Recap: Building on a Housing Recovery
at The Street - Wed Aug 20, 4:00AM CDT
The trading panel looked at Home Depot, home builders and Apple.
Drug Approvals, Financial Results, Market Activity, New Mobile Applications, and Company Updates - Research Reports on Intercept, Exact Sciences, Thermo Fisher Scientific, Illumina and Agilent
PR Newswire - Fri Aug 15, 8:00AM CDT
Today, Analysts Review released its research reports regarding Intercept Pharmaceuticals, Inc. (NASDQ: ICPT), Exact Sciences Corporation (NASDAQ: EXAS), Thermo Fisher Scientific, Inc. (NYSE: TMO), Illumina Inc. (NASDAQ: ILMN) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5768-100free.
Biotech Stock Mailbag: Exact Sciences, Galena, Amgen
at The Street - Fri Aug 15, 6:22AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Kate Spade and Flowers Foods are big market movers
AP - Tue Aug 12, 3:42PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Why Exact Sciences (EXAS) Stock Is Gaining Today
at The Street - Tue Aug 12, 10:33AM CDT
Exact Sciences (EXAS) shares are climbing after the company's non-invasive cancer detection test was approved by the FDA.
FDA Approves Exact Sciences' Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test
PR Newswire - Tue Aug 12, 6:00AM CDT
Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company's noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy-to-use screening test they can do in the privacy of their own home.
FDA approves first DNA-based test for colon cancer
By MATTHEW PERRONE - AP - Mon Aug 11, 5:43PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Monday approved the first screening test for colon cancer that uses patients' DNA to help spot potentially deadly tumors and growths.
Exact Sciences Earnings Hindsight: Up 1.1% in Last 20 Days (EXAS)
Comtex SmarTrend(R) - Mon Aug 11, 12:22PM CDT
20 days ago, on July 22nd, 2014, Exact Sciences (NASDAQ:EXAS) reported its earnings. Analysts, on average, expected a loss of $0.24 per share on sales of $123.0 thousand. The company actually reported a loss of $0.24 per share on sales of $0.0 thousand, beating EPS estimates by $0.00 and matching revenue estimates. Shares of Exact Sciences have climbed from $16.49 to $16.67, representing a gain of 1.1% since the company reported earnings 20 days ago.
